Adenosine and schizophrenia: mechanisms and therapies
Adenosine and schizophrenia: mechanisms and therapies
批准号:
8900336
负责人:
Detlev Boison
金额:
$41.25万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-20 至 2016-06-30
关键词:
AcidsAddressAdenosineAdolescenceAdultAdult ChildrenAffectAntipsychotic AgentsAstrocytesBehaviorBehavioralBehavioral AssayBehavioral SymptomsBrainCognitiveDataDevelopmentDiet therapyDorsalEngineeringEnvironmental Risk FactorFaceFunctional disorderFundingGlutamatesHealthHomeostasisImmuneImpairmentInfectionInjection of therapeutic agentInterventionKnowledgeLinkMaternal-Fetal ExchangeMeasuresModelingMusMutationNeurogliaNeuronsNeurotransmittersPhasePhenotypePhysiologyPlayPositioning AttributePrecipitating FactorsPregnancyPreventionRegulationResearchRoleSchizophreniaSignal TransductionSymptomsSystemTaxesTelencephalonTestingTherapeuticTherapeutic InterventionTransgenic MiceWorkbasebehavior testendophenotypefetalfetus cellglutamatergic signalinginhibitor/antagonistketogenic dietmind controlnestin proteinnovelnovel therapeuticsoffspringpostnatalpregnantprenatalpreventtrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This renewal application continues to address the 'adenosine hypothesis of schizophrenia', which predicts that disruption of adenosine (ADO) homeostasis in the brain produces behavioral effects mimicking specific schizophrenia (SZ) symptoms. Studies from our previous funding period demonstrated that disruption of ADO homeostasis in the adult brain affected multiple brain circuits implicated in the pathophysiology of SZ. Importantly, we provided evidence for the antipsychotic potential of ADO augmentation therapy. Our renewal application will assess the contribution of developmental dysfunction of ADO homeostasis to the genesis of SZ-related symptoms in mice. Our proposed work is based on the following rationale: (i) ADO regulation plays a critical role in brain development. (ii) The
placental ADO-barrier plays a key role in separating the maternal from the fetal ADO-system. (iii) Prenatal immune stimulation, an environmental risk factor for SZ, challenges developmental ADO homeostasis. (iv) ADO homeostasis in the adult brain is under the control of astrocytes; therefore impairment of astrocyte physiology will affect ADO homeostasis. (v) Data from our previous funding period demonstrated an anti-SZ potential of therapeutic ADO augmentation. Here, we will address the CENTRAL HYPOTHESIS that developmental dysfunction of adenosine homeostasis contributes to the pathophysiology of schizophrenia; and that adenosine-based interventions provide new opportunities for therapeutic interventions. Using a novel set of transgenic mice with conditional mutations affecting ADO-homeostasis during fetal brain development, ADO-based therapeutic manipulations at the maternal/fetal interface in the mouse gestational infection model of SZ, ADO-based therapeutic interventions during adolescence and adulthood, and behavioral assays to tax selected SZ-related behavioral traits, we will address our hypothesis in three Specific Aims: (1) Test the hypothesis that fetal disruption of ADO homeostasis affects brain development. (2) Test the hypothesis that dysregulation of ADO homeostasis contributes to the neurodevelopmental derailments implicated in the gestational infection model of SZ. (3) Test the prediction that postnatal ADO augmenting interventions can prevent or suppress SZ-related symptoms in offspring derived from a prenatal immune challenge. Significance and Impact: The proposed project will define the role(s) of specific adenosinergic dysfunctions during fetal brain development as possible precipitating factor for the development of SZ. Importantly, our research will test preventative therapeutic measures directly interfering with ADO signaling at the maternal/fetal inter- face. In addition our findings will address a critical gap in knowledge about the potential link between ADO, brain development, glia, and SZ - a much understudied research field. By identifying the therapeutic potential of restoring astrocyte-based ADO-dependent homeostatic control of brain functions in adolescence and adult- hood, our studies will define a novel therapeutic principle for
the prevention and treatment of SZ.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fnmol.2016.00026
发表时间:
2016
期刊:
Frontiers in molecular neuroscience
影响因子:
4.8
作者:
[Boison D]
通讯作者:
Boison D
DOI:
10.1016/j.neuropharm.2011.01.048
发表时间:
2012-03
期刊:
NEUROPHARMACOLOGY
影响因子:
4.7
作者:
[Boison, Detlev, Singer, Philipp, Shen, Hai-Ying, Feldon, Joram, Yee, Benjamin K.]
通讯作者:
Yee, Benjamin K.
DOI:
10.1016/j.neuropharm.2015.04.031
发表时间:
2015-10
期刊:
Neuropharmacology
影响因子:
4.7
作者:
[Boison D, Aronica E]
通讯作者:
Aronica E
DOI:
10.1037/a0016676
发表时间:
2009-10
期刊:
BEHAVIORAL NEUROSCIENCE
影响因子:
1.9
作者:
[Singer, Philipp, Boison, Detlev, Moehler, Hanns, Feldon, Joram, Yee, Benjamin K.]
通讯作者:
Yee, Benjamin K.
DOI:
10.1037/a0021556
发表时间:
2010-12
期刊:
BEHAVIORAL NEUROSCIENCE
影响因子:
1.9
作者:
[Dubroqua, Sylvain, Singer, Philipp, Boison, Detlev, Feldon, Joram, Moehler, Hanns, Yee, Benjamin K.]
通讯作者:
Yee, Benjamin K.
共 17 条
Therapies for epilepsy prevention - focus on adenosine
-
批准号:10655634
-
项目类别:
-
资助金额:$43.22万
-
财政年份:2022
-
负责人:Detlev Boison
-
依托单位:
Adenosine receptor mediated therapies for SUDEP
-
批准号:10197236
-
项目类别:
-
资助金额:$34.34万
-
财政年份:2018
-
负责人:Detlev Boison
-
依托单位:
Adenosine receptor mediated therapies for SUDEP
-
批准号:10409789
-
项目类别:
-
资助金额:$34.34万
-
财政年份:2018
-
负责人:Detlev Boison
-
依托单位:
Adenosine kinase antisense gene therapy for temporal lobe epilepsy.
-
批准号:9011551
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2015
-
负责人:Detlev Boison
-
依托单位:
Glycine augmentation therapy for the treatment of epilepsy
-
批准号:8841417
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2014
-
负责人:Detlev Boison
-
依托单位:
Glycine augmentation therapy for the treatment of epilepsy
-
批准号:9250824
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2014
-
负责人:Detlev Boison
-
依托单位:
Glycine augmentation therapy for the treatment of epilepsy
-
批准号:8753797
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2014
-
负责人:Detlev Boison
-
依托单位:
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis
-
批准号:9912862
-
项目类别:
-
资助金额:$54.69万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
The Role of Adenosine in Ketogenic Diet Therapy
-
批准号:8517220
-
项目类别:
-
资助金额:$40.92万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
The Role of Adenosine in Ketogenic Diet Therapy
-
批准号:8333420
-
项目类别:
-
资助金额:$42.4万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
The Role of Adenosine in Ketogenic Diet Therapy
-
批准号:8050452
-
项目类别:
-
资助金额:$42.28万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis
-
批准号:10161864
-
项目类别:
-
资助金额:$57.29万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
The Role of Adenosine in Ketogenic Diet Therapy
-
批准号:8143345
-
项目类别:
-
资助金额:$42.4万
-
财政年份:2010
-
负责人:Detlev Boison
-
依托单位:
Astrocyte dysfunction in epileptogenesis: the role of adenosine
-
批准号:7637610
-
项目类别:
-
资助金额:$31.05万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Adenosine and schizophrenia: mechanisms and therapies
-
批准号:8213765
-
项目类别:
-
资助金额:$32.82万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Astrocyte dysfunction in epileptogenesis: the role of adenosine
-
批准号:7807909
-
项目类别:
-
资助金额:$30.74万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Astrocyte dysfunction in epileptogenesis: the role of adenosine
-
批准号:8051813
-
项目类别:
-
资助金额:$30.43万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Adenosine and schizophrenia: mechanisms and therapies
-
批准号:8760708
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Astrocyte dysfunction in epileptogenesis: the role of adenosine
-
批准号:8239599
-
项目类别:
-
资助金额:$30.43万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
Adenosine and schizophrenia: mechanisms and therapies
-
批准号:8411243
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2009
-
负责人:Detlev Boison
-
依托单位:
海外基金